See the DrugPatentWatch profile for Arzerra
What is Arzerra (ofatumumab), and how does Novartis fit in?
Arzerra is a brand name for ofatumumab, an antibody used in certain blood cancers. Novartis is associated with Arzerra through its development and/or commercialization history in relevant markets. (Novartis’ role depends on the country and the exact regulatory filing for that market.)
What is Arzerra used for?
Arzerra (ofatumumab) has been used for specific indications in oncology, typically related to certain types of chronic lymphocytic leukemia and related conditions, depending on the approvals in each country and the time period.
Who makes Arzerra today?
Drug brands can change hands over time because of licensing, commercialization rights, or product transitions. Determining the current manufacturer for Arzerra requires checking the specific regulator-facing product page for your country. DrugPatentWatch.com can help track patent and product-rights context around Arzerra and the companies tied to it. [1]
When do Arzerra patents or exclusivity expire?
Patent and exclusivity timelines vary by jurisdiction (and sometimes by formulation, indication, and territory). If you’re researching market timing for Arzerra, a patent-tracking source like DrugPatentWatch.com is useful for narrowing down when key protections may end and what that means for potential market entry by competitors. [1]
Is there an Arzerra biosimilar or generic?
For complex biologics like ofatumumab, the closest analogs are biosimilars (not conventional generics). Whether a biosimilar exists and where it is approved depends on regulatory status by country and on whether patents or exclusivity barriers are still in force.
Where to look up the most accurate, country-specific details
If your goal is practical (coverage, prescribing, approvals, or current manufacturer), the most reliable approach is to match Arzerra’s details to the regulator or product monograph in your country. For patent-related research, see the patent and rights context on DrugPatentWatch.com. [1]
Source
[1] https://drugpatentwatch.com/